Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308031440> ?p ?o ?g. }
- W4308031440 endingPage "96" @default.
- W4308031440 startingPage "91" @default.
- W4308031440 abstract "The combination of immune-checkpoint inhibitors (ICI) and platinum-pemetrexed chemotherapy (CT) in first-line setting improved survival outcomes of advanced non-small cell lung cancer (NSCLC) patients. Among the various adverse events, renal toxicity can be a relevant safety issue.We conducted a single-center, observational retrospective study including consecutive patients treated with upfront CT-ICI for advanced nonsquamous NSCLC to investigate incidence and clinical characteristics of acute kidney injury (AKI) using 'Acute Kidney Injury Working Group of Kidney Disease: Improving Global Outcomes' (KDIGO) definition.A total of 89 patients received a first-line CT/ICI. The median age was 69 years. 60.7 % were male, and 87.6 % had an ECOG PS of 0-1. 92.1 % had a baseline glomerular filtration rate of at least 60 ml/min. According to KDIGO criteria, 25 (28 %) patients developed AKI. Considering risk factors for AKI onset, patients receiving >10 cycles of CT/ICI were more likely to experience AKI (p < 0.001). No other associations were found with other variables, including concomitant medications. Any component of the treatment was discontinued (pemetrexed pembrolizumab or both) in 10 (40 %) patients, and 9 patients (36 %) were addressed to nephrological consultation. These patients had higher mean creatinine variation from baseline (1 vs 0.6 mg/dl, p = 0.025) and creatine level (1.8 vs 1.4 mg/dl, p = 0.015), but lower eGFR (35.7 vs 54.2 ml/min, p = 0.011) in comparison to patients not addressed. No patients had microscopic hematuria or pyuria, but mild proteinuria (<0.8 g/24 h) was found in 4 patients. A renal biopsy was performed on 3 patients, revealing acute tubule interstitial nephritis (ATIN), karyomegalic interstitial nephritis, and acute tubular necrosis (ATN).Renal toxicity represents a challenging adverse event that could negatively impact outcomes of metastatic nonsquamous NSCLC patients receiving CT/ICI demanding a multidisciplinary approach." @default.
- W4308031440 created "2022-11-07" @default.
- W4308031440 creator A5007030465 @default.
- W4308031440 creator A5015826182 @default.
- W4308031440 creator A5021943811 @default.
- W4308031440 creator A5024256526 @default.
- W4308031440 creator A5034544353 @default.
- W4308031440 creator A5042643177 @default.
- W4308031440 creator A5046723233 @default.
- W4308031440 creator A5059865280 @default.
- W4308031440 creator A5061014687 @default.
- W4308031440 creator A5068554930 @default.
- W4308031440 creator A5071447422 @default.
- W4308031440 creator A5072521541 @default.
- W4308031440 creator A5076616410 @default.
- W4308031440 creator A5082172565 @default.
- W4308031440 date "2022-12-01" @default.
- W4308031440 modified "2023-10-17" @default.
- W4308031440 title "Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience" @default.
- W4308031440 cites W1521544422 @default.
- W4308031440 cites W1967752491 @default.
- W4308031440 cites W1970809248 @default.
- W4308031440 cites W1971821333 @default.
- W4308031440 cites W1976143883 @default.
- W4308031440 cites W2014985862 @default.
- W4308031440 cites W2151327647 @default.
- W4308031440 cites W2400238036 @default.
- W4308031440 cites W2413514895 @default.
- W4308031440 cites W2461672733 @default.
- W4308031440 cites W2572174216 @default.
- W4308031440 cites W2589000900 @default.
- W4308031440 cites W2606925757 @default.
- W4308031440 cites W2769873219 @default.
- W4308031440 cites W2888503493 @default.
- W4308031440 cites W2914287567 @default.
- W4308031440 cites W2914696936 @default.
- W4308031440 cites W2952666958 @default.
- W4308031440 cites W2969665548 @default.
- W4308031440 cites W2984413960 @default.
- W4308031440 cites W2999959360 @default.
- W4308031440 cites W3009099064 @default.
- W4308031440 cites W3022032819 @default.
- W4308031440 cites W3037575240 @default.
- W4308031440 cites W3090114622 @default.
- W4308031440 cites W3121907365 @default.
- W4308031440 cites W3132634779 @default.
- W4308031440 cites W3133368011 @default.
- W4308031440 cites W3136141307 @default.
- W4308031440 doi "https://doi.org/10.1016/j.lungcan.2022.10.007" @default.
- W4308031440 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36356493" @default.
- W4308031440 hasPublicationYear "2022" @default.
- W4308031440 type Work @default.
- W4308031440 citedByCount "2" @default.
- W4308031440 countsByYear W43080314402023 @default.
- W4308031440 crossrefType "journal-article" @default.
- W4308031440 hasAuthorship W4308031440A5007030465 @default.
- W4308031440 hasAuthorship W4308031440A5015826182 @default.
- W4308031440 hasAuthorship W4308031440A5021943811 @default.
- W4308031440 hasAuthorship W4308031440A5024256526 @default.
- W4308031440 hasAuthorship W4308031440A5034544353 @default.
- W4308031440 hasAuthorship W4308031440A5042643177 @default.
- W4308031440 hasAuthorship W4308031440A5046723233 @default.
- W4308031440 hasAuthorship W4308031440A5059865280 @default.
- W4308031440 hasAuthorship W4308031440A5061014687 @default.
- W4308031440 hasAuthorship W4308031440A5068554930 @default.
- W4308031440 hasAuthorship W4308031440A5071447422 @default.
- W4308031440 hasAuthorship W4308031440A5072521541 @default.
- W4308031440 hasAuthorship W4308031440A5076616410 @default.
- W4308031440 hasAuthorship W4308031440A5082172565 @default.
- W4308031440 hasConcept C121608353 @default.
- W4308031440 hasConcept C126322002 @default.
- W4308031440 hasConcept C126894567 @default.
- W4308031440 hasConcept C143998085 @default.
- W4308031440 hasConcept C159641895 @default.
- W4308031440 hasConcept C2776256026 @default.
- W4308031440 hasConcept C2776694085 @default.
- W4308031440 hasConcept C2777240266 @default.
- W4308031440 hasConcept C2777701055 @default.
- W4308031440 hasConcept C2778239845 @default.
- W4308031440 hasConcept C2778653478 @default.
- W4308031440 hasConcept C2780057760 @default.
- W4308031440 hasConcept C2780472472 @default.
- W4308031440 hasConcept C2781068499 @default.
- W4308031440 hasConcept C71924100 @default.
- W4308031440 hasConceptScore W4308031440C121608353 @default.
- W4308031440 hasConceptScore W4308031440C126322002 @default.
- W4308031440 hasConceptScore W4308031440C126894567 @default.
- W4308031440 hasConceptScore W4308031440C143998085 @default.
- W4308031440 hasConceptScore W4308031440C159641895 @default.
- W4308031440 hasConceptScore W4308031440C2776256026 @default.
- W4308031440 hasConceptScore W4308031440C2776694085 @default.
- W4308031440 hasConceptScore W4308031440C2777240266 @default.
- W4308031440 hasConceptScore W4308031440C2777701055 @default.
- W4308031440 hasConceptScore W4308031440C2778239845 @default.
- W4308031440 hasConceptScore W4308031440C2778653478 @default.
- W4308031440 hasConceptScore W4308031440C2780057760 @default.
- W4308031440 hasConceptScore W4308031440C2780472472 @default.
- W4308031440 hasConceptScore W4308031440C2781068499 @default.